CLNN Clene Inc.

Nasdaq clene.com


$ 12.27 $ 2.50 (25 %)    

Friday, 31-Oct-2025 19:16:34 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 12.5
$ 9.97
$ 9.80 x 9
$ 12.65 x 16
$ 9.95 - $ 12.75
$ 2.28 - $ 12.75
478,166
na
124.88M
$ 0.75
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 03-24-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-13-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-13-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 03-11-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-29-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 d-boral-capital-maintains-buy-on-clene-maintains-23-price-target

D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.

 d-boral-capital-maintains-buy-on-clene-maintains-23-price-target

D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ: CLNN) with a Buy and maintains $23 price target.

 benchmark-maintains-buy-on-clene-lowers-price-target-to-31

Benchmark analyst Bruce D. Jackson maintains Clene (NASDAQ:CLNN) with a Buy and lowers the price target from $33 to $31.

 clene-files-prospectus-supplement-for-628m-shares

 - SEC Filing

 clene-inc-announces-new-preclinical-data-showing-that-its-lead-candidate-cnm-au8-improved-cellular-health-in-a-dopaminergic-neuron-model-of-parkinsons-disease

Novel human preclinical neuronal model for Parkinson's disease demonstrated CNM-Au8's ability to improve mitochondrial ...

 d-boral-capital-maintains-buy-on-clene-maintains-23-price-target

D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.

 canaccord-genuity-maintains-buy-on-clene-lowers-price-target-to-48

Canaccord Genuity analyst Sumant Kulkarni maintains Clene (NASDAQ:CLNN) with a Buy and lowers the price target from $83 to $48.

 d-boral-capital-maintains-buy-on-clene-maintains-23-price-target

D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.

 clene-q2-eps-078-misses-047-estimate-sales-27000k-miss-52833k-estimate

Clene (NASDAQ:CLNN) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.47) by 64...

 d-boral-capital-maintains-buy-on-clene-maintains-23-price-target

D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.

 d-boral-capital-maintains-buy-on-clene-maintains-23-price-target

D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION